<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255008</url>
  </required_header>
  <id_info>
    <org_study_id>P04212</org_study_id>
    <nct_id>NCT00255008</nct_id>
  </id_info>
  <brief_title>Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)</brief_title>
  <official_title>SEASON South East Asian Study Of Novel Genotypes in Hepatitis C Infection: Pegylated-Interferon and Ribavirin Therapy (PEGATRON REDIPEN Combination Therapy (PEG-Intron® REDIPEN Plus REBETOL®)) in Treatment Naive Patients With Genotypes 1, 6, 7, 8, 9: A Comparison of Race and Genotype on Treatment Outcome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter clinical trial designed to compare the efficacy of 48 weeks of therapy
      with pegylated (PEG)-Interferon/ribavirin in Southeastern Asian patients with genotype 1
      chronic hepatitis C with 48 weeks of therapy with PEG-Interferon/ribavirin in Caucasian
      patients with genotype 1 chronic hepatitis C. This study is also designed to provide a
      randomized comparison of 24 weeks versus 48 weeks of therapy with PEG-Interferon/ribavirin
      in Southeastern Asian patients with genotypes 6-9. The primary endpoint is sustained
      virologic response, as defined by negative hepatitis C virus (HCV) ribonucleic acid (RNA) in
      serum at 24 weeks after therapy completion.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment
  </why_stopped>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Subjects Who Achieved a Sustained Virologic Response (SVR)</measure>
    <time_frame>24 weeks after completion of either up to 24 or 48 weeks of therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR is defined as negative hepatitis C virus ribonucleic acid (HCV RNA) in serum at 24 weeks after therapy completion. The study was terminated early due to slow enrollment. The primary outcome measure could not be assessed.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Genotype 1 SEA PEG-IFN/RIB 48 w</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Genotype 1 hepatitis C virus (HCV)-infected Southeastern Asian (SEA) subjects treated for up to 48 weeks with PEG-Intron (peginterferon alfa-2b; PEG-IFN) REDIPEN and REBETOL (ribavirin; RIB) combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1 Caucasian PEG-IFN/RIB 48 w</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Genotype 1 HCV-infected Caucasian subjects treated for up to 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 24 w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 24 weeks with PEG-Intron REDIPEN and REBETOL combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 48 w</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peginterferon alfa-2b</intervention_name>
    <description>Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks</description>
    <arm_group_label>Genotype 1 SEA PEG-IFN/RIB 48 w</arm_group_label>
    <arm_group_label>Genotype 1 Caucasian PEG-IFN/RIB 48 w</arm_group_label>
    <arm_group_label>Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 48 w</arm_group_label>
    <other_name>SCH 54031, PegIntron REDIPEN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks</description>
    <arm_group_label>Genotype 1 SEA PEG-IFN/RIB 48 w</arm_group_label>
    <arm_group_label>Genotype 1 Caucasian PEG-IFN/RIB 48 w</arm_group_label>
    <arm_group_label>Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 48 w</arm_group_label>
    <other_name>SCH 18908, REBETOL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peginterferon alfa-2b</intervention_name>
    <description>Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks</description>
    <arm_group_label>Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 24 w</arm_group_label>
    <other_name>SCH 54031, PegIntron REDIPEN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 24 weeks</description>
    <arm_group_label>Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 24 w</arm_group_label>
    <other_name>SCH 18908, REBETOL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Comply with all current Australian Schedule of Pharmaceutical Benefits S100
             eligibility criteria.

          -  Able to give written informed consent and adhere to study visit schedule.

          -  South East Asian ethnicity (except for Caucasian Gt1/1b in comparator arm) i.e. born
             in Vietnam, Cambodia, Laos, Thailand, Hong Kong, and China or have both parents born
             in these countries.

          -  Genotype 1, 1a, 1b, 6, 6a, 6b, 7, 8, or 9, as classified by INNO-LiPA assay.

          -  Hemoglobin &gt;=120 g/L (females), &gt;=130 g/L (males).

          -  Platelet count &gt;=100 x 10^9/L.

          -  Neutrophil count &gt;=1.5 x 10^9/L.

          -  Negative pregnancy test for females.

          -  Thyroid stimulating hormone (TSH) within normal limits.

        Exclusion Criteria:

          -  Participation in any other investigational drug program within 30 days of the
             Screening Visit.

          -  Human immunodeficiency virus (HIV) antibody positive or hepatitis B surface antigen
             (HBsAg) positive.

          -  Genotype 2, 3, 4, or 5, as classified by INNO-LiPA assay.

          -  Non South East Asian ethnicity (unless recruited to Caucasian GT1 comparator arm).

          -  Evidence of liver disease due to other disorders (e.g., hemachromatosis, Wilson's
             disease).

          -  Ongoing drug or alcohol abuse which in the opinion of the investigator would
             jeopardize the patient's ability to comply with study requirements.

          -  Inability to comply with study requirements for other reasons.

          -  Decompensated cirrhosis (Ascites, history of encephalopathy or bleeding varices,
             serum albumin &lt;35 g/L, prothrombin time (PT) prolonged by greater than 3 sec).

          -  Present or prior history of severe psychiatric disease requiring hospitalization or
             medication.

          -  History of severe seizure disorder.

          -  History of autoimmune disorders (e.g., rheumatoid arthritis, inflammatory bowel
             disease, immune thrombocytopenic purpura, systemic lupus erythematosus, or other
             mixed connective tissue disease, psoriasis, optic neuritis).

          -  Poorly controlled thyroid disease.

          -  Creatinine clearance &lt;50 mL/min.

          -  Severe cardiovascular disease.

          -  Hepatocellular cancer.

          -  Clinically significant ophthalmologic disorders.

          -  Hemoglobinopathies (e.g., thalassemia, sickle-cell anemia).

          -  Treatment or recent treatment with immunosuppressive agents (excluding short-term
             corticosteroid withdrawal), and immunosuppressed transplant recipients scheme.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 4, 2015</lastchanged_date>
  <firstreceived_date>November 15, 2005</firstreceived_date>
  <firstreceived_results_date>December 5, 2008</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic hepatitis C</keyword>
  <keyword>pegylated interferon alfa-2b</keyword>
  <keyword>ribavirin</keyword>
  <keyword>Asia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
